The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Bad drop for ProventionBio on Friday. Maybe why KS avoided the diabetes market.
Foralumab is particularly novel in its approach so should be clear of a similar problem in the future.
https://finance.yahoo.com/amphtml/news/provention-bio-shares-crash-40-113430352.html
They have similarities but are different in two ways
Tils product is fully humanised and it’s delivery method is different ( nasal not IV )
We are competitors not partners ...
Both FORALUMAB and Teplizumab are similar , however FORALUMAB is considered to be safer than Teplizumab which is administered by injection. FORALUMAB can be administered orally or nasally. Type 1 Diabetes is a HUGE HUGE market, I am disappointed with Kunwar Shailubhai. Instead of focusing on this, we pivot to Covid-19 !
TILS , to my knowledge have nothing to do with Teplizumab , which initially came out of the university of Michigan ....
Jab102,
Tils is partnering with Provention Bio. I fink!
Can someone more knowledgeable please confirm if thats correct or what the actual cross reference with Tils refers to.
To re-state, FORALUMAB is the only fully human anti-CD3 monoclonal antibody in clinical development in the world.
To cover off:-
1.) Liver diseases.
2.) NASH.
3.) PBs.
4.) Colitis.
5.) MS.
6.) TID.
7.) IBD.
8.) Psoriasis.
9.) Rheumatoid Arthritis.
Are we talking multi billion $ products in multi billion $ markets?
You betcha.
vbw
Sorry, need to correct my post, should have stated does anyone know whether TILS pursued this.
Does anyone know what happened to this?????
https://ir.tizianalifesciences.com/news-releases/news-release-details/tiziana-life-sci-plc-teplizumab-article
Provention Bio Inc is using Teplizumab to treat Type 1 Diabetes (showing positive results), it is going for Phase 3 FDA approval in July
https://proventionbio.com/autoimmune-candidates